AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca's stock price fell 7 percent following a Financial Times report that the company had held merger discussions with Bristol Myers Squibb over several months. The reported deal value was estimated at $400 billion. Neither company released an official statement in response to the report.

Next story